ProPhase Labs, Inc. Debt Conversion, Converted Instrument, Amount
ProPhase Labs, Inc. (PRPH) reported Debt Conversion, Converted Instrument, Amount of $1.15 million for the 0-month period ending 2022-02-28, per its 10-Q filed 2022-11-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2025-04-01
- 2022-02-28: Debt Conversion, Converted Instrument, Amount 0 month $1.15M; Debt Conversion, Converted Instrument, Amount $1.20M; Debt Conversion, Converted Instrument, Amount as first filed $1.15M.
| Period end | Debt Conversion, Converted Instrument, Amount 0 month | Debt Conversion, Converted Instrument, Amount | Debt Conversion, Converted Instrument, Amount as first filed |
|---|---|---|---|
| 2022-02-28 | $1.15M 10-Q · filed 2022-11-10 | $1.20M 10-K · filed 2025-04-01 | $1.15M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |